Screener
MoonLake Immunotherapeutics MLTX Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands) | March 31, 2026 / Amortized cost | March 31, 2026 / Gross unrealized gains | Fair value |
|---|---|---|---|
| Eurocommercial Papers | $29,536 | $181 | $29,717 |
| Certificates of Deposit | 29,533 | 181 | 29,714 |
| Total | $59,069 | $362 | $59,431 |
| Of which classified within short-term marketable debt securities | 59,069 | 362 | 59,431 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's unrealized gains on investments?
- MoonLake Immunotherapeutics (MLTX) reported unrealized gains on investments of $362K in Q1 2026.
- How has MoonLake Immunotherapeutics's unrealized gains on investments changed year-over-year?
- MoonLake Immunotherapeutics's unrealized gains on investments decreased by 86.3% year-over-year, from $2.65M to $362K.
Ask your AI about MoonLake Immunotherapeutics's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude